Peer review reports
From: A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients
Original Submission |
15 Jan 2016 |
Submitted |
Original manuscript
|
|
Author responded |
Author comments
|
Resubmission - Version 2 |
|
Submitted |
Manuscript version 2
|
|
Author responded |
Author comments
|
|
Reviewed |
Reviewer Report
|
Resubmission - Version 3 |
|
Submitted |
Manuscript version 3
|
|
Reviewed |
Reviewer Report
|
Resubmission - Version 4 |
|
Submitted |
Manuscript version 4
|
Publishing |
11 Aug 2016 |
Editorially accepted |
|
17 Aug 2016 |
Article published |
10.1186/s12885-016-2709-z
|
Learn about peer review